In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard therapy for patients with chronic lymphocytic leukemia (CLL) who have ...

Panelists discuss how strategic sequencing decisions in frontline CLL therapy, informed by new evidence from the Rhodes et al. ASH 2024 study, have downstream implications for managing treatment ...

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitor selection in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) depends on key factors including prior therapy ...

The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.

At a median duration of follow-up of 6.6 months, treatment with pirtobrutinib reduced the risk of progression or death by 42%. The Food and Drug Administration (FDA) has approved Jaypirca ® ...

Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...

ORLANDO, Fla. — Patients who took pirtobrutinib (Jaypirca) had a similar overall response rate to those who took ibrutinib. This was the case for those with both treatment-naive and ...

Many patients with chronic lymphocytic leukemia (CLL) are treated with two- or three-drug regimens, but for some patients just one drug may be enough. Particularly for older patients or those who are ...

Nurix Therapeutics, Inc. has announced that data from its ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) will be presented at two major scientific conferences. The trial focuses on ...

SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...